Cargando…

Survival Outcomes in Patients With Hormone Receptor–Positive Metastatic Breast Cancer With Low or No ERBB2 Expression Treated With Targeted Therapies Plus Endocrine Therapy

IMPORTANCE: Approximately 45% to 60% of hormone receptor (HR)–positive metastatic breast cancer (mBC) shows a low-level expression of ERBB2. Low ERBB2 expression is defined as ERBB2 immunohistochemical expression of 1+ or 2+ with a negative ERBB2 amplification by in situ hybridization. The efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mouabbi, Jason A., Singareeka Raghavendra, Akshara, Bassett, Roland L., Hassan, Amy, Tripathy, Debasish, Layman, Rachel M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2023
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176119/ https://www.ncbi.nlm.nih.gov/pubmed/37166793 http://dx.doi.org/10.1001/jamanetworkopen.2023.13017

Ejemplares similares

Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies
por: Mouabbi, Jason A., et al.
Publicado: (2022)

Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes
por: Carausu, Marcela, et al.
Publicado: (2022)

ODP647 Nuclear ERα and NAMPT Crosstalk in Metastatic Breast Tumors
por: Mogol, Ayca, et al.
Publicado: (2022)

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: A Randomized Clinical Trial
por: Sledge, George W., et al.
Publicado: (2019)

ODP563 Breast Cancer With Liver Metastasis Responds Poorly to Fulvestrant-Based Combination Therapy and Chemotherapy
por: Chien, Christine, et al.
Publicado: (2022)

Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France
por: de Calbiac, Ombline, et al.
Publicado: (2022)

Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer
por: Lin, Mingxi, et al.
Publicado: (2020)

Endocrine therapy combined with targeted therapy in hormone receptor-positive metastatic breast cancer
por: Bian, Li, et al.
Publicado: (2020)

Association of Endocrine Therapy With Overall Survival in Women With Small, Hormone Receptor–Positive, ERBB2-Negative Breast Cancer
por: Ma, Sung Jun, et al.
Publicado: (2020)

Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer
por: Garber, Haven R., et al.
Publicado: (2022)

LPTO-08. INTRATHECAL TRASTUZUMAB PLUS/MINUS IT TOPOTECAN FOR PATIENTS WITH HER2+ BREAST CANCER AND LEPTOMENINGEAL METASTASIS
por: Trevino, Christopher R, et al.
Publicado: (2019)

Evaluation of Information Theoretic Network Meta-analysis to Rank First-Line Anticancer Regimens for Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
por: Li, Xuanyi, et al.
Publicado: (2022)

Capecitabine in Combination with Endocrine Therapy as Maintenance Therapy after Bevacizumab Plus Paclitaxel Induction Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: KBCSG-TR1214
por: Masuda, Norikazu, et al.
Publicado: (2021)

Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment
por: Liu, Shuying, et al.
Publicado: (2023)

Racial Differences in Patient-Reported Symptoms and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage, Hormone Receptor–Positive Breast Cancer
por: Hu, Xin, et al.
Publicado: (2022)

Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer
por: Le, Vivian, et al.
Publicado: (2021)

Neoadjuvant Chemotherapy or Endocrine Therapy for Invasive Ductal Carcinoma of the Breast With High Hormone Receptor Positivity and Human Epidermal Growth Factor Receptor 2 Negativity
por: Zhang, Jiaqiang, et al.
Publicado: (2021)

RETRACTION: Challenges of Combined Everolimus/Endocrine Therapy in Hormone Receptor-Positive Metastatic Breast Cancer
por: Porta, Camillo
Publicado: (2014)

Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment
por: Liu, Shuying, et al.
Publicado: (2023)

Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor–Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002)
por: Hua, Xin, et al.
Publicado: (2022)

Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China
por: Yang, Jiao, et al.
Publicado: (2023)

Trends in endocrine therapy prescription and survival in patients with non-metastatic hormone receptor positive breast cancer treated with endocrine therapy: A population based-study
por: Mamguem Kamga, Ariane, et al.
Publicado: (2021)

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial
por: Schmid, Peter, et al.
Publicado: (2019)

Refractory microsatellite stable metastatic colorectal cancer with ERBB2/ERBB3 mutation may be preferred population for regorafenib plus PD-1 inhibitor therapy: a real-world study
por: Dai, Xuan, et al.
Publicado: (2023)

Updates in endocrine therapy for metastatic breast cancer
por: Manohar, Poorni M., et al.
Publicado: (2022)

Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer
por: Houston, S J, et al.
Publicado: (1999)

Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 Trial
por: Cortés, Javier, et al.
Publicado: (2020)

Hormonal treatment combined with targeted therapies in endocrine-responsive and HER2-positive metastatic breast cancer
por: Montagna, Emilia, et al.
Publicado: (2019)

Endocrinology and hormone therapy in breast cancer: Endocrine therapy in premenopausal women
por: Pritchard, Kathleen
Publicado: (2005)

Endocrine resistance in breast cancer: new roles for ErbB3 and ErbB4
por: Sutherland, Robert L
Publicado: (2011)

Influencers of the Decision to Undergo Contralateral Prophylactic Mastectomy among Women with Unilateral Breast Cancer
por: Singareeka Raghavendra, Akshara, et al.
Publicado: (2021)

The Impact of Treatment for Smoking on Breast Cancer Patients’ Survival
por: Singareeka Raghavendra, Akshara, et al.
Publicado: (2022)

The role of hormonal factors and endocrine therapy in ovarian cancer
por: Serkies, Krystyna, et al.
Publicado: (2013)

Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 (ERBB2)–Positive Breast Cancer
por: Braman, Nathaniel, et al.
Publicado: (2019)

Real-world effectiveness and sensitivity of palbociclib plus endocrine therapy in HR+/HER2– patients with metastatic breast cancer
por: Li, Jingping, et al.
Publicado: (2021)

Effect of Reduced-Dose Capecitabine Plus Cetuximab as Maintenance Therapy for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Clinical Trial
por: Wang, Lu, et al.
Publicado: (2020)

Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial
por: Boige, Valérie, et al.
Publicado: (2023)

Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor‐positive/human epidermal growth factor receptor 2‐negative metastatic breast cancer
por: Gelmon, Karen A., et al.
Publicado: (2019)

Metastatic breast cancer: Endocrine therapy landscape reshaped
por: Salkeni, Mohamad Adham, et al.
Publicado: (2017)

Association of Endocrine Therapy Initiation Timeliness With Adherence and Continuation in Low-Income Women With Breast Cancer
por: Sood, Nikita, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3ae8cro894oscp8p5qqn7c03tp